Depomed (DEPO) Misses Q4 EPS by 13c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.

Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Nvidia’s AI dominance funds historic $150 billion buyback
• Oppenheimer says these stocks could be new AI software winners
• Vestis names Russell Tiejema as CFO, reaffirms fiscal 2026 outlook